Armando Santoro

机构：Humanitas University, Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS Humanitas Research Hospital · ORCID：0000-0003-1709-9492

发表论文 1836 篇 · 总被引 79446 次 · h-index 122

代表论文

• Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study (2025 · Blood · 被引 7)
• Intratumoral microbiome in breast cancer: A hidden player in tumor development, progression and treatment response (2025 · Critical Reviews in Oncology/Hematology · 被引 5)
• Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study (2025 · Journal for ImmunoTherapy of Cancer · 被引 4)
• Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge (2025 · ESMO Open · 被引 4)
• Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial (2026 · The Lancet · 被引 3)
• Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial (2025 · Blood Neoplasia · 被引 3)